SAN FRANCISCO — Like a defibrillator shock for flat-lined M&A lawyers, a string of multibillion-dollar deals among pharmaceutical companies has given new life to Silicon Valley dealmakers.
Roche agreed to pay $46.8 billion for the rest of South San Francisco’s Genentech Inc. on March 12. Already a majority shareholder, the Swiss drug company raised its offer from $44 billion, made last July in an unsolicited advance. Latham & Watkins represented the special committee of independent Genentech directors that had final say on the deal, while Wilson Sonsini Goodrich & Rosati was hired by Genentech. Davis Polk & Wardwell did the deal for Roche.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
